Share Price | Petros Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: How big is Petros Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, Petros Pharmaceuticals, Inc. has a market capitalization of 0.93 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Petros Pharmaceuticals reported net sales of 3.73 million and a net profit of -13.35 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -7.47 million and total assets of 10.64 million.

Q: What does Petros Pharmaceuticals, Inc. do?

Overview: Petros Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Net Profit: -1 Million (Quarterly Results - Mar 2025) Market Cap: USD 0.93 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.93 Return on Equity: 83.46% Price to Book: -0.10Contact Details: Registrar Address: Not available.

Q: Should I buy, sell or hold Petros Pharmaceuticals, Inc.?

Based on the current situation of Petros Pharmaceuticals, Inc., it would be advisable to hold your position in the stock rather than buy or sell. The company is facing significant challenges, including poor management efficiency reflected in a low return on capital employed (ROCE) of 0% and a negative net worth, which raises concerns about its financial health. Additionally, the company has experienced a decline in net sales at an annual rate of -25.81% over the past five years, indicating poor long-term growth prospects. The recent flat results as of March 25 further suggest a lack of momentum.Moreover, the stock is considered risky, especially given its negative EBITDA and the fact that it has generated no returns over the past year, despite a rise in profits. On a slightly positive note, there has been an increase in participation from institutional investors, who have raised their stake by 2.33% in the last quarter. This could indicate some level of confidence from more sophisticated investors, but it does not negate the underlying risks.Overall, holding your investment while monitoring the company's performance and any potential changes in its financial situation would be the most prudent approach at this time.

Q: Is Petros Pharmaceuticals, Inc. technically bullish or bearish?

As of 1 July 2025, the technical trend for Petros Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while the weekly MACD and KST show mildly bullish signals. The RSI is bullish on the weekly timeframe but shows no signal on the monthly. Bollinger Bands are sideways weekly and mildly bearish monthly, and Dow Theory indicates no trend in both weekly and monthly perspectives. In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -99.72% versus the S&P's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

34.06 k

Shareholding (Sep 2025)

FII

0.01%

Held by 4 FIIs

DII

99.98%

Held by 0 DIIs

Promoter

0.00%

How big is Petros Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Petros Pharmaceuticals, Inc. has a market capitalization of 0.93 million, with net sales of 3.73 million and a net profit of -13.35 million over the last four quarters. The company reported shareholder's funds of -7.47 million and total assets of 10.64 million as of Dec 24.

View full answer

What does Petros Pharmaceuticals, Inc. do?

22-Jun-2025

Petros Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $1 million and a market cap of $0.93 million. Key metrics include a return on equity of 83.46% and a debt-to-equity ratio of 0.93.

View full answer

Should I buy, sell or hold Petros Pharmaceuticals, Inc.?

22-Jun-2025

Is Petros Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of July 1, 2025, Petros Pharmaceuticals, Inc. is in a mildly bearish trend, with daily moving averages indicating bearishness, while weekly indicators show mixed signals, and the stock has underperformed the S&P 500 with a year-to-date return of -99.72%.

View full answer

Compare Petros Pharmaceuticals, Inc. with Similar Stocks

Universe Pharmaceuticals, Inc.ZyVersa Therapeutics, Inc.Artelo Biosciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.80

Return on Equity

-176.24%

Price to Book

0.11

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-92.05%

6 Months

-97.91%

1 Year

-98.4%

2 Years

-99.67%

3 Years

-100.0%

4 Years

-100.0%

5 Years

0.0%

Petros Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-31.83%

EBIT Growth (5y)

11.87%

EBIT to Interest (avg)

-9.39

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.93

Sales to Capital Employed (avg)

-0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.12%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.11

EV to EBIT

1.01

EV to EBITDA

1.40

EV to Capital Employed

0.43

EV to Sales

-2.12

PEG Ratio

Dividend Yield

ROCE (Latest)

42.27%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bearish

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.01%)

Foreign Institutions

Held by 4 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -600.00% vs 116.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.80",
          "val2": "-1.30",
          "chgp": "-38.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.30",
          "val2": "1.60",
          "chgp": "-118.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.00",
          "val2": "0.40",
          "chgp": "-600.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -12.07% vs -3.33% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -74.39% vs 59.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.10",
          "val2": "5.80",
          "chgp": "-12.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.40",
          "val2": "-7.30",
          "chgp": "-1.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.50",
          "chgp": "20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.80",
          "val2": "2.60",
          "chgp": "-246.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.30",
          "val2": "-8.20",
          "chgp": "-74.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,014.10%",
          "val2": "-1,848.40%",
          "chgp": "-16.57%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.80

-1.30

-38.46%

Interest

0.00

Exceptional Items

-0.30

1.60

-118.75%

Consolidate Net Profit

-2.00

0.40

-600.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -600.00% vs 116.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

5.10

5.80

-12.07%

Operating Profit (PBDIT) excl Other Income

-7.40

-7.30

-1.37%

Interest

0.60

0.50

20.00%

Exceptional Items

-3.80

2.60

-246.15%

Consolidate Net Profit

-14.30

-8.20

-74.39%

Operating Profit Margin (Excl OI)

-2,014.10%

-1,848.40%

-16.57%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -12.07% vs -3.33% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -74.39% vs 59.00% in Dec 2023

All Annual Results

Company CV

About Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Petros Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Petros Pharmaceuticals, Inc.?

Watch in Real-Time

What does Petros Pharmaceuticals, Inc. do?

Should I buy, sell or hold Petros Pharmaceuticals, Inc.?

Is Petros Pharmaceuticals, Inc. technically bullish or bearish?

Compare Petros Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Petros Pharmaceuticals, Inc.

Company Coordinates